Literature DB >> 33580915

Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Shabarinath Nambiar1, Dino Bee Aik Tan2,3, Britt Clynick2,3, Sze How Bong1, Catherine Rawlinson4, Joel Gummer1, Tamera J Corte5,6, Ian Glaspole7,8, Yuben P Moodley2,3,9,10, Robert Trengove1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by airway inflammation and progressive airflow limitation, whereas idiopathic pulmonary fibrosis (IPF) is characterised by a restrictive pattern due to fibrosis and impaired gas exchange. We undertook metabolomic analysis of blood samples in IPF, COPD and healthy controls (HC) to determine differences in circulating molecules and identify novel pathogenic pathways. An untargeted metabolomics using an ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometer (UHPLC-QTOF-MS) was performed to profile plasma of patients with COPD (n = 21), and IPF (n = 24) in comparison to plasma from healthy controls (HC; n = 20). The most significant features were identified using multiple database matching. One-way ANOVA and variable importance in projection (VIP) scores were also used to highlight metabolites that influence the specific disease groups. Non-polar metabolites such as fatty acids (FA) and membrane lipids were well resolved and a total of 4805 features were identified. The most prominent metabolite composition differences in lipid mediators identified at ∼2-3 fold higher in both diseases compared to HC were palmitoleic acid, oleic acid and linoleic acid; and dihydrotestosterone was lower in both diseases. We demonstrated that COPD and IPF were characterised by systemic changes in lipid constituents such as essential FA sampled from circulating plasma.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  COPD; IPF; metabolomics; plasma

Mesh:

Year:  2021        PMID: 33580915     DOI: 10.1002/prca.202000039

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  4 in total

1.  SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism.

Authors:  Yue Zhang; Ting Li; Miaoxia Pan; Wei Wang; Wenhui Huang; Yafei Yuan; Zhanzhan Xie; Yixin Chen; Jun Peng; Xu Li; Ying Meng
Journal:  J Transl Med       Date:  2022-05-14       Impact factor: 8.440

Review 2.  Challenges for Clinical Drug Development in Pulmonary Fibrosis.

Authors:  Eric S White; Matthew Thomas; Susanne Stowasser; Kay Tetzlaff
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

3.  Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication.

Authors:  Benjamin Seeliger; Alfonso Carleo; Pedro David Wendel-Garcia; Jan Fuge; Ana Montes-Warboys; Sven Schuchardt; Maria Molina-Molina; Antje Prasse
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

4.  Identification and immune characteristics of molecular subtypes related to fatty acid metabolism in idiopathic pulmonary fibrosis.

Authors:  Fan Yang; Zhaotian Ma; Wanyang Li; Jingwei Kong; Yuhan Zong; Bilige Wendusu; Qinglu Wu; Yao Li; Guangda Dong; Xiaoshan Zhao; Ji Wang
Journal:  Front Nutr       Date:  2022-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.